Bisphosphonates Reduce Fracture Risk in Prostate Cancer Patients
Researchers have found in a large randomized trial that men with metastatic prostate cancer receiving androgen deprivation therapy (ADT) had a significantly lower risk of fractures when treated with a bisphosphonate alongside standard of care (SOC).
The study, published in the Annals of Oncology journal, suggests the benefits of bisphosphonates in reducing fracture risk.
Men with metastatic prostate cancer receiving ADT had a significantly lower risk of fractures when treated with a bisphosphonate alongside standard of care.
In a separate note, a model called PanEcho was trained on transthoracic echocardiographic (TTE) data from Yale New Haven Health System (YNHHS) between January 2016 and June 2022, but it is not directly related to the study on bisphosphonates.
Author's summary: Bisphosphonates reduce fracture risk.
More News
- OpenAI completes for-profit shift, gives Microsoft 27% stake
- Fiddler Scott Woods doesn't dip his bow into politics
- Atalanta v AC Milan: Confirmed line-ups as Rossoneri look to end hosts' unbeaten start
- Kieran McKenna Linked with Celtic Job
- Sudan Red Crescent says 5 volunteers killed, 3 missing in North Kordofan amid RSF attacks
- Nokia commits to full AI-RAN GPU play on new Nvidia RAN compute platform - The Mobile Network
- Al Nassr Al-Ittihad Jeddah 28 10 2025 Live Score and Match Summary
- Nicole Kidman thriving while Keith Urban struggles after split
- The museum and the mass grave: How colonial powers curate our pain
- Dodgers pitcher, EIU alum Will Klein wins World Series game 3